n3 PUFA and Muscle-disuse Atrophy in Young Women

Effects of n3 PUFA Supplementation on the Attenuation of Muscle Disuse Atrophy in Young Women

This study will examine the influence of n3 PUFA supplementation on the rate of muscle atrophy in women undergoing 2 weeks of unilateral limb immobilization. Assessments in skeletal muscle strength and skeletal muscle volume will also me made before, after and in recovery from immobilization.

Study Overview

• Status: Completed
• Conditions: Muscle Atrophy
• Intervention / Treatment: Dietary supplement: n3 PUFA-enriched fish oil; Dietary supplement: Placebo

Detailed Description

Biological aging is associated with the loss of skeletal muscle mass and strength resulting in compromised metabolic function and mobility. Throughout life, individuals will also experience periods of reduced physical activity/muscle disuse that independently lower muscle mass and strength accelerating the aging process. The losses in muscle mass with aging and disuse are underpinned by feeding-induced declines in rates of muscle protein synthesis. Thus, strategies to enhance muscle protein synthesis could have clinical implications for those who wish to maintain metabolic health and function during times of muscle disuse.

Supplementation with n3 PUFA-enriched fish oil has been shown to potentiate rates of muscle protein synthesis in response to simulated feeding in both younger and older adults. Fish oil supplementation also has been efficacious in enhancing skeletal muscle strength during a period of resistance exercise training. However, no study has examined the impact of fish oil supplementation to enhance muscle protein synthesis and offset declines in muscle mass/strength during a period of immobilization.

• Study Type: Interventional
• Enrollment (Actual): 20
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • Hamilton, Ontario, Canada, L8S 4K1
      • Exercise Metabolism Research Laboratory, McMaster Univeristy

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 30 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Female
• Aged 18-30 years

Exclusion Criteria:

• Take any analgesic or anti-inflammatory drugs(s), prescription or non-prescription, chronically will be excluded
• A history of neuromuscular problems or muscle and/or bone wasting diseases
• Any acute or chronic illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, insulin- or non-insulin dependent diabetes or other metabolic disorders-all ascertained through medical history screening questionnaires
• Use medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications)
• Fish allergy

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: n3 PUFA; Intervention: n3 PUFA (3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day)	Dietary supplement: n3 PUFA-enriched fish oil; 3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day
Placebo Comparator: Placebo; Intervention: Organic Sunflower Oil 5000mg per day	Dietary supplement: Placebo; Organic Sunflower Oil 5000mg per day

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Muscle Volume	Change in Muscle Volume Measured by Magnetic Resonance Imaging	Baseline (0 days), After (14 days) of unilateral limb immobilization and at 14 days post immobilization

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Integrated Rates of Muscle Protein Synthesis	Change in Muscle Protein Synthesis	Before (0 days), During (0-14 days inclusive), and After (14-28 days inclusive) of unilateral limb immobilization
Skeletal Muscle Strength	Change in Skeletal Muscle Strength	Before (0 days), After (14 days) of unilateral limb immobilization and at 14 days Post immobilization
Muscle Lipid Composition	Change in Muscle Lipid Composition	Baseline (-28 days), and at Before (0 days), After (14 days) of unilateral limb immobilization and at 14 days Post immobilization

Collaborators and Investigators

• Sponsor: McMaster University
• Collaborators: University of Guelph

Study record dates

Study Major Dates

• Study Start (Actual): February 28, 2017
• Primary Completion (Actual): February 28, 2018
• Study Completion (Actual): February 28, 2018

Study Registration Dates

• First Submitted: February 15, 2017
• First Submitted That Met QC Criteria: February 16, 2017
• First Posted (Actual): February 23, 2017

Study Record Updates

• Last Update Posted (Actual): March 22, 2018
• Last Update Submitted That Met QC Criteria: March 20, 2018
• Last Verified: March 1, 2018

More Information

Terms related to this study

• Keywords: n3 PUFA
• Additional Relevant MeSH Terms: Nervous System Diseases; Neurologic Manifestations; Musculoskeletal Diseases; Muscular Diseases; Neuromuscular Diseases; Neuromuscular Manifestations; Pathological Conditions, Anatomical; Muscular Atrophy; Atrophy; Muscular Disorders, Atrophic
• Other Study ID Numbers: 1457

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No